Active, not recruitingPhase 3NCT06311721
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MD, M.DAmgen
- Intervention
- ABP 234(drug)
- Enrollment
- 315 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Precision NextGen Oncology and Research Center, Beverly Hills, California, United States
- TOI Clinical Research, Cerritos, California, United States
- Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- PIH Health Hospital, Whittier, California, United States
- Millennium Oncology - Hollywood, Hollywood, Florida, United States
- BRCR Medical Center Inc., Tamarac, Florida, United States
- Accellacare Duly, Plainfield, Illinois, United States
- Accellacare of McFarland, Ames, Iowa, United States
- Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States
- North Shore Hematology-Oncology Associates P.C. d/b/a New York Cancer & Blood Specialists, Shirley, New York, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- Millennium Research and Clinical Development, LLC, Houston, Texas, United States
- Texas Oncology, P.A, San Antonio, Texas, United States
- Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06311721 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →